"The president pledged America's steadfast ongoing support for the people of India, who have been impacted by the recent surge in the COVID-19 cases," White House Press Secretary Jen Psaki told reporters at her daily news conference.
'There is no shortage of any APIs (active pharmaceutical ingredients) in the country'
If a retail investor wants exposure to a healthcare ETF, it should be a part of his satellite portfolio, suggests Sanjay Kumar Singh.
The ministry said there should be no interruptions in the services of small retail shops, large organised retail stores and e-commerce companies.
"The deal is being implemented. We witnessed attempts on the part of the US to undermine this cooperation and make India obey the American orders to follow the American vision of how this region should be developed," Russian Foreign Minister Sergey Lavrov said.
Ahead of the first meeting of the top decision-making body in nearly eight months, finance ministers of eight states ruled by non-Bharatiya Janata Party and like-minded parties -- Rajasthan, Punjab, Chhattisgarh, Tamil Nadu, Maharashtra, Jharkhand, Kerala and West Bengal -- have devised a joint strategy to press for a zero tax rate on Covid essentials, sources said.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
As India holds its breath for the Covid vaccination to be begin, Sudhir Bisht provides a quick checklist of what you must know about the vaccines that will be administered to citizens.
Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
At a time when the country's medical infrastructure has become incapable of handling the pressure of Covid's deadly second wave, a parallel wave of conmen, black marketers and counterfeiters can be witnessed across the country. Geetanjali Krishna reports.
Currently, the country is using two 'made-in India' jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.
The central government should provide for free vaccination to all Indian citizens and greatly ramp up RT-PCR testing in both rural and urban areas, a group of former civil servants said on Thursday in an open letter to Prime Minister Narendra Modi.
Currently, domestic supplies and commercial imports of vaccines attract a 5 per cent Goods and Services Tax, while COVID drugs and oxygen concentrators attract a 12 per cent levy.
On production capacity of Covishield, the vaccine being manufactured and supplied by Serum in India under a licensing agreement with Oxford and AstraZeneca, he said the present capacity is 130 million doses per month and always try to increase it further.
The Hyderabad-based manufacturer uses a proprietary adjuvant Algel-IMDG, which has now proven to be a safe and effective adjuvant, especially to stimulate memory T cell responses.
According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the "entire production" at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
'I cannot cope with the demand. It will take us a couple of months to ramp up production.'
'I want to thank Prime Minister Modi of India for allowing us to have what we requested for the problem arose and he was terrific. We will remember it'
"The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine," the consent form said.
In the last one week several companies have had to face the hurdle of making a distinction between what's essential and what's not. To help them the government has now clarified that grocery would include hygiene products such as hand wash, soaps, disinfectants, body wash, shampoo, surface cleaners, detergents, tissue paper, toothpaste, oral care, sanitary pads, diapers, chargers and battery cells, etc.
It is one of 42 drug-making factories in India that the FDA has banned in recent years
The Supreme Court has asked the Centre to place on record all relevant documents and file notings reflecting its thinking culminating in the COVID-19 vaccination policy, and the purchase history till date of all jabs including Covaxin, Covishield and Sputnik V.
US-India Business Council President Nisha Biswal believes once the economic activity and demand resumes, India could hold the potential for diversification of supply chains and manufacturing.
It had not been able to meet the deadline so far, though investigation into the matter was over, sources said.
Overall, the credit profiles of players will be supported by healthy balance sheets and liquidity. Prudence in capital and development expenditure, efficient working-capital management, and recent equity raising will help sustain credit metrics in FY22.
After staging a strong recovery from COVID-induced slowdown in 2021, India's exports are likely to extend the growth story to the New Year also on increased demand in the global markets, boost in domestic manufacturing due to production-linked incentive schemes and implementation of some interim trade pacts. Expectations of positive growth in the country's exports are also backed up by the outlook of the World Trade Organisation (WTO) which predicts a 4.7 per cent expansion in the global merchandise trade volume in 2022. Exporters believe that the outbound shipments would cross $400 billion mark in this fiscal going by the current momentum and may reach $475 billion in 2022-23.
Medical experts have warned that the volume of vaccine available to fight the coronavirus or SARS-CoV-2 in coming years is expected to fall far short of global demand, despite an unprecedented effort to manufacture billions of doses.
Maharashtra is expecting its active caseload to reach 11.9 lakh by April 30, compared to the current active caseload of 5.64 lakh, Thackeray said.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.
India is struggling with a second wave of the pandemic with more than 3,00,000 daily new coronavirus cases being reported in the past few days, and hospitals are reeling under a shortage of medical oxygen and beds.
'After the discovery of the biomarkers, Calpain and Inflammasomes, we know we have a biomarker to target.' 'That way, we can use the biomarkers for an early diagnosis of blood clotting due to hypoxia or low oxygen in the tissues, and can save a life.'
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.
Of the 23.9 million vaccinators who provide vaccination under the universal immunisation programme, 15.4 million will be used for Covid vaccination.
One Chinese source informed ANI that 10 million new infections are probably occurring daily in China.
"At least for 15 days if people stay strictly indoors, like last year, we may expect better results. Please advise your government," the high court said.
Under the proposed rules, individuals or companies will have to register with the central licensing authority to run an e-pharmacy; state-wide registration is not required.
The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals. The Pune-based Serum Institute of India, the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.
Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances